Society Letters

DAA Letter on Questions from the National Clinical Care Commission

February 03, 2020

To: Linda Harris, Designated Federal Officer, National Clinical Care Commission 

"The DAA urges regulatory reforms that would allow CMS flexibility to cover innovative diabetes technologies and services, so that as new diabetes technologies and services are approved by the FDA, there is a coverage pathway in Medicare for them. Rapid advances in this space have outpaced Medicare’s existing coverage and reimbursement guidelines resulting in overly complicated or even a lack of, access processes for patients, health care professionals and suppliers."

arrow Read the Full Letter

Last Updated:
Take Action

Make Your Voice Heard

Take Action
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.